Swiss germ-cell cancer consensus recommendations

Swiss germ-cell cancer consensus recommendations

Approximately 420 men are diagnosed with germ-cell cancer (GCC) in Switzerland each year. Recent international guidelines outline management issues, but many aspects remain controversial in an area of highly individualised treatments. Even more than in other tumour types, in GCC the challenge is t...

Full description

Bibliographic Details
Main Authors:	Jörg Beyer, Dominik Berthold, Peter-Karl Bode, Richard Cathomas, Christian D. Fankhauser, Stefanie Fischer, Silke Gillessen, Tobias Gross, Thomas Hermanns, Friedemann Honecker, Anja Lorch, Aurelius Omlin, Alexandros Papachristofilou, Beat Roth, Christian Rothermundt, Roland Seiler, Martin Spahn, Frank Stenner, Emanuel Bührer
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2021-08-01
Series:	Swiss Medical Weekly
Online Access:	https://www.smw.ch/index.php/smw/article/view/3057

Similar Items

Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence
by: Ailsa J. Christiansen, et al.
Published: (2022-12-01)

Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer
by: Arnoud J. Templeton, et al.
Published: (2023-08-01)

Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses
by: Manolis Pratsinis, et al.
Published: (2022-06-01)

Reply to Julian Chavarriaga and Robert Hamilton's Letter to the Editor re: Manolis Pratsinis, Christian Fankhauser, Katerina Pratsinis, et al. Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses. Eur Urol Open Sci 2022;40:16–8. Should We Be Afraid of Surveillance? Clinically Meaningful Reasons Why Offering Surveillance for Incidentally Detected Small Testicular Masses Remains a Safe Approach
by: Manolis Pratsinis, et al.
Published: (2022-11-01)

First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)
by: Stefanie Fischer, et al.
Published: (2024-10-01)

Perioperative complications and oncological outcomes of post-chemotherapy retroperitoneal lymph node dissection in patients with germ cell cancer at two high-volume university centres in Switzerland – a retrospective chart review
by: Marco Notarfrancesco, et al.
Published: (2023-04-01)

The Value of Tumour Markers in the Detection of Relapse—Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study
by: Stefanie Fischer, et al.
Published: (2023-04-01)

CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors
by: Christian Daniel Fankhauser, et al.
Published: (2019-08-01)

Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009–2018
by: Stefanie Aeppli, et al.
Published: (2022-06-01)

Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy – protocol of a multicentre, single arm phase 2 trial (SAKK 06/19)
by: Richard Cathomas, et al.
Published: (2023-06-01)

Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort
by: D Helbling, et al.
Published: (2010-07-01)

Micro-RNA expression in cisplatin resistant germ cell tumor cell lines
by: Meineke Viktor, et al.
Published: (2011-05-01)

Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma
by: Christian D. Fankhauser, et al.
Published: (2023-10-01)

Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)
by: Christian Rothermundt, et al.
Published: (2018-07-01)

Oncological Follow-up Strategies for Testicular Germ Cell Tumours: A Narrative Review
by: Ernest Kaufmann, et al.
Published: (2022-10-01)

Clinicopathological characteristics, risk factors and outcomes of patients with para- /testicular sarcoma: A systematic review
by: J.N. Fronzaroli, et al.
Published: (2020-07-01)

Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment
by: Dominik Menges, et al.
Published: (2023-05-01)

Excellent survival in relapsed stage I testicular cancer
by: Philip Speicher, et al.
Published: (2023-09-01)

Updates on Radiotherapy for Localized Prostate Cancer
by: Alexandros Papachristofilou
Published: (2023-12-01)

Seminal vesicle sparing robotic radical prostatectomy – no different interpretation of postoperative PSA follow-up required?
by: Patrick Betschart, et al.
Published: (2019-01-01)

Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer.
by: Kathrin Endt, et al.
Published: (2017-01-01)

Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice
by: Richard Cathomas, et al.
Published: (2020-05-01)

Marine Compounds and Cancer: Updates 2020
by: Sergey A. Dyshlovoy, et al.
Published: (2020-12-01)

Marine Compounds and Cancer: Updates 2022
by: Sergey A. Dyshlovoy, et al.
Published: (2022-12-01)

Marine Compounds and Autophagy: Beginning of a New Era
by: Sergey A. Dyshlovoy, et al.
Published: (2018-07-01)

Marine Compounds and Cancer: 2017 Updates
by: Sergey A. Dyshlovoy, et al.
Published: (2018-01-01)

Marine Compounds and Cancer: Where Do We Stand?
by: Sergey A. Dyshlovoy, et al.
Published: (2015-09-01)

Marine Drugs Acting as Autophagy Modulators
by: Sergey A. Dyshlovoy, et al.
Published: (2020-01-01)

Marine Compounds and Cancer: The First Two Decades of XXI Century
by: Sergey A. Dyshlovoy, et al.
Published: (2019-12-01)

Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade
by: Heinz Läubli, et al.
Published: (2017-06-01)

Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs
by: Turco F, et al.
Published: (2022-09-01)

Retroperitoneal teratoma with somatic malignant transformation: A papillary renal cell carcinoma in a testicular germ cell tumour metastasis following platinum-based chemotherapy
by: Zeh Nina, et al.
Published: (2013-02-01)

Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first‐line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)
by: Ben Tran, et al.
Published: (2020-01-01)

Reinforcement Learning Your Way: Agent Characterization through Policy Regularization
by: Charl Maree, et al.
Published: (2022-03-01)

Effectiveness of Flexible Ureterorenoscopy Versus Extracorporeal Shock Wave Lithotripsy for Renal Calculi of 5–15 mm: Results of a Randomized Controlled Trial
by: Christian Daniel Fankhauser, et al.
Published: (2021-03-01)

Can Interpretable Reinforcement Learning Manage Prosperity Your Way?
by: Charl Maree, et al.
Published: (2022-06-01)

Consensus on the Screening, Staging, Treatment, and Surveillance of Localized, Recurrent, and Metastatic Prostate Cancer: The First Global Prostate Cancer Consensus Conference for Developing Countries
by: Fernando Cotait Maluf, et al.
Published: (2021-12-01)

T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
by: Laurent Julien, et al.
Published: (2013-01-01)

Good germs, bad germs: Citizen science and microbiology
by: Lorimer, J, et al.
Published: (2017)

Extracting salient features for network intrusion detection using machine learning methods
by: Ralf C. Staudemeyer, et al.
Published: (2014-06-01)